On Thursday, Needham, a financial services firm, lowered its price target on shares of iRhythm Technologies (NASDAQ:IRTC), a digital healthcare company, to $96.00 from the previous $119.00. Despite the reduction, the firm maintained its Buy rating on the stock.
iRhythm Technologies reported third-quarter revenue that exceeded consensus estimates and the company's management has narrowed its revenue guidance for 2024. The growth in volume was widespread, with notable momentum in its Zio AT product, which was attributed to the opening of new accounts.
The company has successfully cleared two catch-up 510(k)s with regulatory authorities, which is a step forward for its product approvals. However, iRhythm plans to postpone the regulatory filing for its Zio MCT product until the third quarter of 2025. This delay is expected to reduce sales estimates for 2025 by approximately $10 million.
Despite the regulatory challenges that have weighed on iRhythm's stock, Needham expressed confidence in the company's ability to maintain high-teens percentage revenue growth and improve profitability. The firm's decision to reiterate the Buy rating reflects this optimism.
The adjustment of the price target to $96 is attributed to the revised sales forecast for 2025 and a slight decrease in the valuation multiples of peer companies. This new price target represents Needham's current valuation of iRhythm Technologies based on these factors.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on iRhythm Technologies' financial position and market performance. The company's market capitalization stands at $2.37 billion, reflecting its significant presence in the digital healthcare sector. iRhythm has demonstrated strong revenue growth, with a 18.81% increase over the last twelve months as of Q2 2024, reaching $537.09 million. This aligns with Needham's confidence in the company's ability to maintain high-teens percentage revenue growth.
However, profitability remains a challenge for iRhythm. An InvestingPro Tip indicates that the company is not profitable over the last twelve months, with a negative operating income of $100.96 million. This is consistent with the article's mention of the company's efforts to improve profitability.
Another InvestingPro Tip suggests that iRhythm operates with a moderate level of debt, which could provide financial flexibility as it navigates regulatory challenges and product development. The company's price-to-book ratio of 23.86 indicates that investors are placing a premium on its future growth potential, despite current profitability issues.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips for iRhythm Technologies, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.